Note that some links may require subscriptions.
FDA approves brexanolone (Zulresso), the first drug specifically for postpartum depression. Check back later on MedPage Today for full story.
And Genentech announced FDA approval of atezolizumab (Tecentriq), in combination with chemotherapy, as initial treatment for extensive-stage small cell lung cancer.
Could Medicare- and Medicaid-subsidized prescriptions for healthy foods help avert a health crisis among American youths? (Inverse, PLOS Medicine)
Vaccination opponents are being blamed for a series of harassment incidents involving anonymous posts to Facebook accounts of parents whose young children died. (CNN)
Cranial irradiation to prevent brain metastases significantly improved overall survival in patients with unresected locally advanced non-small cell lung cancer. (NRG Oncology)
AbbVie’s trials of venetoclax (Venclexta) in multiple myeloma are on partial clinical hold, after excess deaths occurred among patients taking it in a phase III trial. (Reuters)
A California jury found that exposure to the herbicide glyphosate (Roundup) was a “substantial factor” in a 70-year-old man’s development of non-Hodgkin lymphoma. (Fox News)
San Francisco officials mull a ban on e-cigarettes until the FDA conducts an adequate review of the products. (Reuters)
A hedge fund manager turned biotech entrepreneur who licenses investigational drugs from other companies chalked up his first big win, as a phase III trial of the overactive bladder drug vibregon met all clinical endpoints. (STAT)
Breast implant maker Sientra got an FDA warning letter for failing to complete a required post-marketing study on time.
Environmental health authorities found no air-quality issues related to a fire that has been burning since Sunday at a suburban Houston petrochemical plant. (ABC News)
Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: [email protected]